Supplementary data - **Anti-obesity effect of hydroethanolic extract of *Hibiscus sabdariffa* L. (Malvaceae) and of *Syzygium cumini* Linn. Skeels (Myrtaceae)**



Figure S1. The total ion current chromatogram obtained through ESI-MS analyses of HSE in negative ion mode.



Figure S2. ESI-MS spectrum of caffeoyl hydroxycitric acid (**1**).



Figure S3. ESI-MS spectrum of hibiscus acid glucoside (**2**).



Figure S4. ESI-MS spectrum of delphinidin-3-sambubioside (**3**).



Figure S5. ESI-MS spectrum of cyanidin-3-sambubioside (**4**).



Figure S6. ESI-MS spectrum of cis-3-O-caffeoylquinic acid (**5**).



Figure S7. ESI-MS spectrum of cis-5-O-caffeoylquinic acid (**6**).



Figure S8. ESI-MS spectrum of myricetin-3-O-arabinorhamnoside (**7**).



Figure S9. ESI-MS/MS spectrum of myricetin-3-O-arabinogalactoside (**8**).



Figure S10. ESI-MS spectrum of rutin xyloside or quercetin-7-O-xyloside-3-O-rutinoside (**9**).



Figure S11. ESI-MS spectrum of quercetin-3-O-sambubioside (**10**).



Figure S12. ESI-MS/MS spectrum of quercetin-3-O-sambubioside (**10**).



Figure S13. ESI-MS/MS spectrum of rutin (**11**).



Figure S14. ESI-MS/MS spectrum of quercetin-3-O-glucoside (**12**).



Figure S15. ESI-MS/MS spectrum of quercetin-3-O-(p-coumaroyl)- sambubioside (**13**).



Figure S16. The total ion current chromatogram obtained through ESI-MS analyses of SCE in negative ion mode.



Figure S17. ESI-MS/MS in negative ion mode of vescalagin (**15**)



Figure S18. ESI-MS/MS in negative ion mode of castalagin (**16**)



Figure S19. ESI-MS/MS in negative ion mode of pedunculagin I - bis-HHDP-glucose (**18**)



Figure S20. ESI-MS/MS in negative ion mode of casuarinin (**19**)



Figure S21. ESI-MS/MS in negative ion mode of punigluconin - 2,3-Di-O-galloyl-4,6-(S)-hexahydroxydiphenoylgluconic acid (**20**)



Figure S22. ESI-MS/MS in negative ion mode of trisgalloyl HHDP glucose (**21**)



Figure S23. ESI-MS/MS in negative ion mode of casuarictin or potentillin (**22**).



Figure S24. ESI-MS/MS in negative ion mode of 1,3-digalloyl-4,6-hexahydroxydiphenoylglucose or heterophylliin A (**23**)



Figure S25. ESI-MS/MS in negative ion mode of 1,2,4,6-tetragalloyl glucose (**24**).



Figure S26. ESI-MS/MS in negative ion mode 1,2,4,6-tetragalloyl glucosyl rhamnoside (**25**)



Figure S27. ESI-MS/MS in negative ion mode of 1,2,3,4,6-pentagalloyl glucose (**26**)



Figure S28. ESI-MS/MS in negative ion mode of myricetin-3-(galloyl)glucoside (**27**)



Figure S29. ESI-MS/MS in negative ion mode of myricetin-3-O-glucoside (**28**)



Figure S30. ESI-MS/MS in negative ion mode of myricetin-3-*O*-rhamnoside – myricitrin (**29**)



Figure S31. ESI-MS/MS in negative ion mode of myricetin-3-*O*-acetyl rhamnoside (**30**).



Figure S32. Forest plot comparing weight gain (g) between treatment groups at 7 days in sub-chronic efficacy.



Figure S33. Forest plot comparing weight gain (g) between treatment groups at 14 days in sub-chronic efficacy.



Figure S34. Forest plot comparing weight gain (g) between treatment groups at 21 days in sub-chronic efficacy.



Figure S35. Forest plot comparing weight gain (g) between treatment groups at 28 days in sub-chronic efficacy.



Figure S36. Forest plot comparing weight gain (g) between treatment and control groups at 7 days in sub-chronic efficacy.



Figure S37. Forest plot comparing weight gain (g) between treatment and control groups at 14 days in sub-chronic efficacy.



Figure S38. Forest plot comparing weight gain (g) between treatment and control groups at 21 days in sub-chronic efficacy.



Figure S39. Forest plot comparing weight gain (g) between treatment groups at 14 days in sub-chronic efficacy.



Figure S40. Bar graph showing the weight gain of the treatment groups in 7 days.



Figure S41. Bar graph showing the weight gain of the treatment groups in 14 days.



Figure S42. Bar graph showing the weight gain of the treatment groups in 21 days.



Figure S43. Bar graph showing the weight gain of the treatment groups in 28 days.